So far, the efforts have been approved by the street: NVS stock has gained 29% in the trailing 52 weeks, compared to a 14% decline by SPDR S&P Pharmaceuticals and 7% gain by the NYSE Arca Pharmaceutical Index.
On average, analysts expect revenues to decline 12% to $11.5 billion in Q2, as the company continues to shed fat. In April, the company completed the spin-off of Alcon, which was a major revenue-generating unit for Novartis.
Separately, it divested three products to Italian pharmaceutical company Recordati for $390 million, jettisoned a JV with GlaxoSmithKline and sold the US oral solid drugs unit to India-based Aurobindo Pharma. Novartis is aiming to put its focus on the Innovative Medicines business.
Second-quarter net income is also projected to decline to $1.20 per share, 9 cents lower than last year. In the trailing four quarters, Novartis has surpassed street estimates in three.
To drive future growth, Novartis has a strong product pipeline including Zolgensma, a treatment of spinal muscular atrophy, which received approval from the Food and Drug Administration (FDA). It also has Entresto and Cosentyx as important growth drivers, besides an investigational drug for sickle cell disease.
Though there have been rumors of the company planning to
acquire Amarin Corp (NASDAQ:
AMRN), the deal has not yet materialized.
The stock has an average 12-month price target of $100, suggesting a 12% upside from the last close.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.